MedTrace Logo

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

NCT00338104 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2009-04-06

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to determine the optimal dose of glargine insulin when converting from intravenous short-acting continuous insulin infusions in surgical and intensive care unit patients using a prospective, controlled, parallel group, randomized study design.

Note: Lantus insulin is the proprietary name for glargine insulin.

Conditions

Interventions

DRUG

insulin glargine

Insulin glargine given at 40% of prior stable drip rate.

DRUG

insulin glargine

Insulin glargine given at 60% of prior stable drip rate.

DRUG

insulin glargine

Insulin glargine given at 80% of prior stable drip rate.

Sponsors & Collaborators

Principal Investigators

  • Mark E Molitch, M.D. · Northwestern University Feinberg School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338104 on ClinicalTrials.gov